CLDF Title
Home | Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
Live CME Meetings Webcasts Slide Library Abstract Library Conference Highlights
Reuters Health Information (2012-11-12): Novartis' Certican succeeds in liver transplant trial

Drug & Device Development

Novartis' Certican succeeds in liver transplant trial

Last Updated: 2012-11-12 18:50:26 -0400 (Reuters Health)

ZURICH (Reuters) - Swiss pharmaceutical company Novartis said on Monday its Certican, an immune system drug also known under the names Afinitor and Votubia, showed positive outcomes in a two-year phase III study in liver transplantation.

The study, which Novartis said was the largest liver transplant trial to date, confirmed the comparative effectiveness of the treatment and the improved renal function in patients previously noted at the 12-month stage.

The trial evaluated the introduction of Certican (everolimus) with reduced exposure of another immunosuppressive drug tacrolimus administered twice-daily starting one month after liver transplantation versus standard-exposure tacrolimus, Novartis said.

The data were presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston.

Certican was approved by European health authorities for use in adult liver transplant patients in October 2012. A decision by the US Food and Drug Administration is expected by the end of 2012, Novartis said.

Under the trade name Certican, everolimus is approved in more than 90 countries to prevent organ rejection for renal and heart transplant patients, Novartis said.

Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Live CME Meetings
Slide Library
Abstract Library
Slide Library
Abstract Library
CLDF Follow Us
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Substance Use Disorder
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2016 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.